Therapure Biopharma Inc.'s Drug Delivery Program Receives Support from The NRC-IRAP

  • Posted on: 26 August 2010
  • By: admin001

Mississauga, Ontario, Canada (August 26th 2010) Therapure Biopharma Inc. (Therapure) today announced receipt of a financial contribution from the National Research Council’s Industrial Research Assistance Program (NRC-IRAP). The funding is to support Therapure’s drug delivery program for the treatment of liver cancer and hepatitis C infection.

Therapure’s lead product for infectious disease is a stable protein-drug conjugate of hemoglobin and ribavirin designed to selectively target the delivery of ribavirin to the liver for the treatment of hepatitis C virus (HCV) infection. Therapure’s lead cancer product is a similar conjugate of hemoglobin and floxuridine, which delivers the powerful chemotherapy drug floxuridine directly to the liver as treatment for primary liver cancer. Both products are based on a core expertise in protein chemistry and cell biology that Therapure scientists have pioneered and applied to the natural and highly specific pathway for hemoglobin metabolism as a means of treating chronic and acute liver diseases with high unmet medical need.

Both drug delivery products are in the pre-clinical stage of development. Therapure has recently completed pre-IND and pre-CTA submissions to the US FDA and Health Canada, respectively, as a key step in defining the clinical and regulatory paths for both products and advancing them products to the clinic and the treatment of patients sooner.

In addition to technical and business advisory services, the financial assistance provided by NRC-IRAP will support funding for continued pre-clinical safety and efficacy studies, and bioanalytical method development.

“Therapure is very proud to have been chosen by NRC-IRAP” said Thomas Wellner, President and CEO of Therapure. “This demonstrates the breadth of Therapure’s capabilities in Product and Method Development.”

ABOUT THERAPURE BIOPHARMA INC.

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, please visit: www.therapurebio.com

Therapure Contacts:

Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204

ceo@therapurebio.com